Source comparison
KPV BPC-157 for IBD Research: Comparison Analysis
KPV (Lys-Pro-Val) NF-κB inhibition, prevents α-MSH degradation by prolyl endopeptidase 54% reduction in TNF-α/IL-6 expression (DSS model, 2023) No human pharmacokinetic data; oral bioavailability unknown Not FDA-approved; research-use only Strongest evidence f
This comparison does not assign a generated winner or score.
- KPV (Lys-Pro-Val)
- NF-κB inhibition, prevents α-MSH degradation by prolyl endopeptidase
- 54% reduction in TNF-α/IL-6 expression (DSS model, 2023)
- No human pharmacokinetic data; oral bioavailability unknown
- Not FDA-approved; research-use only
- Strongest evidence for acute cytokine suppression. Mechanism distinct from biologics but untested in chronic human IBD
- BPC-157
- VEGF upregulation, eNOS stabilization, accelerated angiogenesis
- 68% reduction in histological inflammation score; complete mucosal healing in 14 days (rat TNBS model, 2023)
- Evidence limited to IP/SC routes; no Phase I human safety trials for IBD
- Most compelling mucosal repair data in preclinical literature. But zero controlled human trials
- Standard Biologics (Infliximab, Adalimumab)
- TNF-α blockade, immune suppression
- 40–60% clinical remission in Phase III human trials (ACCENT I, CLASSIC I)
- Systemic immunosuppression, increased infection risk, loss of response over time
- FDA-approved for moderate-to-severe IBD
- Proven efficacy in humans but mechanism doesn't address mucosal repair deficit
- Corticosteroids (Prednisone, Budesonide)
- Glucocorticoid receptor activation, broad anti-inflammatory effect
- Rapid symptom control in 70–90% of acute flares
- Bone density loss, hyperglycemia, adrenal suppression with prolonged use
- FDA-approved for IBD flare management
- Effective for acute inflammation but unsuitable for maintenance. Taper required